{"id":"NCT03683030","sponsor":"Biosense Webster, Inc.","briefTitle":"Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation","officialTitle":"Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-22","primaryCompletion":"2022-02-18","completion":"2022-02-18","firstPosted":"2018-09-25","resultsPosted":"2025-08-15","lastUpdate":"2025-08-15"},"enrollment":397,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atrial Fibrillation"],"interventions":[{"type":"DEVICE","name":"Multi-Electrode RF Balloon Catheter","otherNames":["HELIOSTAR"]}],"arms":[{"label":"Treatment Group","type":"EXPERIMENTAL"}],"summary":"The primary objective of this clinical investigation is to demonstrate safety and effectiveness of the Multi-Electrode RF Balloon catheter for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation.","primaryOutcome":{"measure":"Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter","timeFrame":"Within 7 days post-procedure (Day of procedure = Day 0)","effectByArm":[{"arm":"Roll-in Phase","deltaMin":4,"sd":null},{"arm":"Main Study","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":18},"locations":{"siteCount":41,"countries":["United States","China","Italy"]},"refs":{"pmids":["39686569"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":94},"commonTop":["Chest pain","Atrial flutter","Dyspnoea","Haematoma","Pyrexia"]}}